Skip to content
10-Q

Quarterly Report

LAVA Therapeutics NV

0001558370-25-007743

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 26.31M sh
Shares Diluted Q1 2025 · Mar 31, 2025 26.89M sh
Shares Diluted Q1 2025 · Mar 31, 2024 26.79M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$11.65M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$843K
Short Term Investments Q1 2025 · Mar 31, 2025 $26.88M
Short Term Investments Q1 2025 · Dec 31, 2024 $41.56M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $39.67M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $35.02M
Stockholders Equity Q1 2025 · Mar 31, 2025 $25.78M
Stockholders Equity Q1 2025 · Dec 31, 2024 $27.75M
Stockholders Equity Q1 2025 · Mar 31, 2024 $50.81M
Stockholders Equity Q1 2025 · Dec 31, 2023 $51.36M
Current Liabilities Q1 2025 · Mar 31, 2025 $10.37M
Current Liabilities Q1 2025 · Dec 31, 2024 $18.01M
Total Liabilities Q1 2025 · Mar 31, 2025 $45.37M
Total Liabilities Q1 2025 · Dec 31, 2024 $53.09M
Current Assets Q1 2025 · Mar 31, 2025 $69.78M
Current Assets Q1 2025 · Dec 31, 2024 $79.3M
Total Assets Q1 2025 · Mar 31, 2025 $71.16M
Total Assets Q1 2025 · Dec 31, 2024 $80.83M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.13
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.02
Eps Basic Q1 2025 · Mar 31, 2025 −$0.13
Eps Basic Q1 2025 · Mar 31, 2024 −$0.02
Sga Expense Q1 2025 · Mar 31, 2025 $3.43M
Sga Expense Q1 2025 · Mar 31, 2024 $3.38M
Rd Expense Q1 2025 · Mar 31, 2025 $4.16M
Rd Expense Q1 2025 · Mar 31, 2024 $5.65M
Net Income Q1 2025 · Mar 31, 2025 −$3.48M
Net Income Q1 2025 · Mar 31, 2024 −$608K
Operating Income Q1 2025 · Mar 31, 2025 −$7.59M
Operating Income Q1 2025 · Mar 31, 2024 −$2.04M
Short Term Debt Q1 2025 · Dec 31, 2024 $4.89M
Capex Q1 2025 · Mar 31, 2024 $23K
Revenue Q1 2025 · Mar 31, 2024 $6.99M